CN106461685B - 神经酰胺及其在诊断cvd中的应用 - Google Patents

神经酰胺及其在诊断cvd中的应用 Download PDF

Info

Publication number
CN106461685B
CN106461685B CN201580031908.1A CN201580031908A CN106461685B CN 106461685 B CN106461685 B CN 106461685B CN 201580031908 A CN201580031908 A CN 201580031908A CN 106461685 B CN106461685 B CN 106461685B
Authority
CN
China
Prior art keywords
ceramide
formula
carbon atoms
alkyl chain
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580031908.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106461685A (zh
Inventor
雷约·拉克索宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zora Biosciences Oy
Original Assignee
Zora Biosciences Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zora Biosciences Oy filed Critical Zora Biosciences Oy
Publication of CN106461685A publication Critical patent/CN106461685A/zh
Application granted granted Critical
Publication of CN106461685B publication Critical patent/CN106461685B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580031908.1A 2014-06-16 2015-06-16 神经酰胺及其在诊断cvd中的应用 Active CN106461685B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462012543P 2014-06-16 2014-06-16
US62/012,543 2014-06-16
US14/677,595 US9347960B2 (en) 2014-06-16 2015-04-02 Ceramides and their use in diagnosing CVD
US14/677,595 2015-04-02
PCT/EP2015/063492 WO2015193325A2 (en) 2014-06-16 2015-06-16 Ceramides and their use in diagnosing cvd

Publications (2)

Publication Number Publication Date
CN106461685A CN106461685A (zh) 2017-02-22
CN106461685B true CN106461685B (zh) 2021-05-25

Family

ID=54835950

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580031908.1A Active CN106461685B (zh) 2014-06-16 2015-06-16 神经酰胺及其在诊断cvd中的应用

Country Status (10)

Country Link
US (5) US9347960B2 (enExample)
EP (2) EP3155440B1 (enExample)
JP (1) JP6774879B2 (enExample)
KR (3) KR102636885B1 (enExample)
CN (1) CN106461685B (enExample)
CA (1) CA2951578A1 (enExample)
MX (1) MX380642B (enExample)
SA (1) SA516380503B1 (enExample)
SG (1) SG11201609621RA (enExample)
WO (1) WO2015193325A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9347960B2 (en) * 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
US10996231B2 (en) * 2014-12-16 2021-05-04 Washington University Ceramides for evaluating risk of cardiovascular disease
US12313634B2 (en) * 2017-11-20 2025-05-27 Zora Biosciences Oy Methods for prediction and early detection of diabetes
CN114062581A (zh) * 2017-12-14 2022-02-18 江苏豪思生物科技有限公司 一种用于评估冠状动脉疾病的试剂盒
WO2020112149A1 (en) * 2018-12-01 2020-06-04 Binhai Industrial Technology Research Institute Of Zhejiang University Methods and compositions for the assessment of acute myocardial infarction (ami)
SG11202105172PA (en) * 2018-12-06 2021-06-29 Zora Biosciences Oy Biomarkers for cardiovascular events
CN112730638B (zh) * 2020-11-25 2022-07-29 首都医科大学附属北京朝阳医院 糖尿病合并心梗代谢标志物、检测试剂及试剂盒
CN112986454A (zh) * 2021-05-18 2021-06-18 天津云检医疗器械有限公司 急性心肌梗死的血清标志物、试剂盒和用途
CN113495160B (zh) * 2021-09-07 2021-11-19 宝枫生物科技（北京）有限公司 用于诊断高原环境下的缺血缺氧性脑病补充神经酸起效的分子标志物及其应用
WO2023108294A1 (en) * 2021-12-17 2023-06-22 National Research Council Of Canada Diagnostic lipid biomarkers for covid-19 and methods for use thereof
CN116500179B (zh) * 2023-04-21 2023-12-26 南京品生医疗科技有限公司 一种血浆中神经酰胺相关因子的原始得分计算及转换方法和系统
CN119198939B (zh) * 2024-08-30 2025-06-03 北京大学第三医院（北京大学第三临床医学院） 神经酰胺的检测试剂盒、应用检测试剂盒检测神经酰胺的方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011092285A2 (en) * 2010-01-29 2011-08-04 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
WO2012136856A1 (en) * 2011-04-08 2012-10-11 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
WO2013014286A2 (en) * 2011-07-28 2013-01-31 Metanomics Gmbh Means and methods for diagnosing and monitoring heart failure in a subject
CN102971633A (zh) * 2010-05-05 2013-03-13 佐拉生物科学公司 针对动脉粥样硬化和心脏血管疾病的脂质组学生物标志
WO2013068374A2 (en) * 2011-11-08 2013-05-16 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
CN103154742A (zh) * 2010-06-20 2013-06-12 佐拉生物科学公司 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
WO2014060486A1 (en) * 2012-10-18 2014-04-24 Metanomics Gmbh Means and methods for determining a clearance normalized amount of a metabolite disease biomarker in a sample

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
CN105008931A (zh) 2013-03-08 2015-10-28 佐拉生物科学公司 非高密度脂蛋白来源的cvd标志物
US9347960B2 (en) * 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011092285A2 (en) * 2010-01-29 2011-08-04 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
CN102971633A (zh) * 2010-05-05 2013-03-13 佐拉生物科学公司 针对动脉粥样硬化和心脏血管疾病的脂质组学生物标志
CN103154742A (zh) * 2010-06-20 2013-06-12 佐拉生物科学公司 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
WO2012136856A1 (en) * 2011-04-08 2012-10-11 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
WO2013014286A2 (en) * 2011-07-28 2013-01-31 Metanomics Gmbh Means and methods for diagnosing and monitoring heart failure in a subject
WO2013068374A2 (en) * 2011-11-08 2013-05-16 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
WO2014060486A1 (en) * 2012-10-18 2014-04-24 Metanomics Gmbh Means and methods for determining a clearance normalized amount of a metabolite disease biomarker in a sample

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency;Kirill Tarasov 等;《J. Clin. Endocrinol. Metab.》;20131115;第99卷(第1期);第E45-E52页 *

Also Published As

Publication number Publication date
CN106461685A (zh) 2017-02-22
EP3155440B1 (en) 2022-04-20
BR112016028534A2 (pt) 2017-08-22
JP6774879B2 (ja) 2020-10-28
US20240183866A1 (en) 2024-06-06
CA2951578A1 (en) 2015-12-23
US20160266152A1 (en) 2016-09-15
KR20240023696A (ko) 2024-02-22
KR102636885B1 (ko) 2024-02-19
US9347960B2 (en) 2016-05-24
WO2015193325A2 (en) 2015-12-23
US11940453B2 (en) 2024-03-26
US20220163547A1 (en) 2022-05-26
US20150362513A1 (en) 2015-12-17
KR102864779B1 (ko) 2025-09-25
MX380642B (es) 2025-03-12
EP3155440A2 (en) 2017-04-19
US20190113531A1 (en) 2019-04-18
SG11201609621RA (en) 2017-01-27
EP4089416A1 (en) 2022-11-16
MX2016016742A (es) 2017-04-27
US11474116B2 (en) 2022-10-18
SA516380503B1 (ar) 2023-03-23
WO2015193325A3 (en) 2016-02-25
KR20170018905A (ko) 2017-02-20
US10197582B2 (en) 2019-02-05
JP2017519989A (ja) 2017-07-20
KR20250139419A (ko) 2025-09-23

Similar Documents

Publication Publication Date Title
US11940453B2 (en) Ceramides and their use in diagnosing CVD
JP5270684B2 (ja) 脂肪肝疾患用のバイオマーカー及びその使用方法
CN108445241B (zh) 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
JP6873490B2 (ja) 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置
JP6404834B2 (ja) インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法
CN104204798A (zh) 膀胱癌的生物标志物和使用所述生物标志物的方法
CN108711451A (zh) 建立急性主动脉夹层诊断标准的方法
US20250264481A1 (en) Methods for prediction and early detection of diabetes
US20190086386A1 (en) USE OF CERAMIDES AND LPLs IN DIAGNOSING CVD
JP2025063061A (ja) 心血管イベントに対するバイオマーカー
US20170343568A1 (en) Prognostic assays for maintenance hemodialysis patients
HK40083140A (en) Ceramides and their use in diagnosing cardiovascular diseases
HK1230721A1 (en) Ceramides and their use in diagnosing cvd
HK1230721B (en) Ceramides and their use in diagnosing cvd
BR112016028534B1 (pt) Composição compreendendo ceramidas, kits e métodos in vitro para determinar o risco do desenvolvimento de doenças ou complicações cardiovasculares, avaliar e escolher tratamentos
US20240044826A1 (en) Metabolic vulnerability analyzed by nmr
KR102897948B1 (ko) 심혈관계 이벤트용 바이오마커
CN119470873A (zh) 代谢综合征的生物标志物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant